Immune cell boost could keep leukemia at bay after transplant
NCT ID NCT05015426
First seen Nov 14, 2025 · Last updated Jun 21, 2026 · Updated 28 times
Summary
This early-phase trial tests whether infusing specially grown donor immune cells (gamma delta T-cells) can prevent acute myeloid leukemia from returning in patients who are at high risk of relapse after a stem cell transplant. About 20 adults aged 18–75 will receive a single infusion of these cells. The study aims to find the safest dose and see if it improves leukemia-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
donor gamma delta T-cells (a type of immune cell)
What this could lead to
If it works, this could offer a new way to prevent leukemia from coming back after a stem cell transplant, without needing long-term drugs.
What could go wrong
This is a very early, small trial (20 people) focused on safety and dosing. The cells may cause graft-versus-host disease or fail to prevent relapse.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.